Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Recently published
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI Insight
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewInfectious diseaseTherapeutics Open Access | 10.1172/jci.insight.140267

TLR-2-mediated activation of innate responses in the upper airways confers anti-viral protection of the lungs

Georgia Deliyannis,1 Chinn Yi Wong,1 Hayley A. McQuilten,1 Annabell Bachem,1 Michele V. Clarke,1 Xiaoxiao Jia,1 Kylie Horrocks,1 Weiguang Zeng,1 Jason Girkin,2 Nichollas E. Scott,1 Sarah L. Londrigan,1 Patrick C. Reading,1 Nathan W. Bartlett,3 Katherine Kedzierska,4 Lorena E. Brown,1 Francesca A. Mercuri,5 Christophe Demaison,5 David C. Jackson,1 and Brendon Y. Chua1

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Deliyannis, G. in: JCI | PubMed | Google Scholar |

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Wong, C. in: JCI | PubMed | Google Scholar

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by McQuilten, H. in: JCI | PubMed | Google Scholar

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Bachem, A. in: JCI | PubMed | Google Scholar

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Clarke, M. in: JCI | PubMed | Google Scholar

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Jia, X. in: JCI | PubMed | Google Scholar

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Horrocks, K. in: JCI | PubMed | Google Scholar

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Zeng, W. in: JCI | PubMed | Google Scholar |

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Girkin, J. in: JCI | PubMed | Google Scholar |

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Scott, N. in: JCI | PubMed | Google Scholar |

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Londrigan, S. in: JCI | PubMed | Google Scholar

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Reading, P. in: JCI | PubMed | Google Scholar |

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Bartlett, N. in: JCI | PubMed | Google Scholar |

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Kedzierska, K. in: JCI | PubMed | Google Scholar |

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Brown, L. in: JCI | PubMed | Google Scholar

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Mercuri, F. in: JCI | PubMed | Google Scholar

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Demaison, C. in: JCI | PubMed | Google Scholar

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Jackson, D. in: JCI | PubMed | Google Scholar |

1Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

2Viral Immunology and Respiratory Disease Group, University of Newcastle, Newcastle, Australia

3Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia

4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

5Ena Therapeutics Pty Ltd, Ena Therapeutics Pty Ltd, Melbourne, Australia

Find articles by Chua, B. in: JCI | PubMed | Google Scholar |

Published February 9, 2021 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.140267.
Copyright © 2021, Deliyannis et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published February 9, 2021 - Version history
View PDF
Abstract

The impact of respiratory virus infections on global health is felt not just during a pandemic but for many, endemic seasonal infections pose an equal and ongoing risk of severe disease. Moreover, vaccines and antiviral drugs are not always effective or available for many respiratory viruses. We investigated how induction of effective and appropriate antigen independent innate immunity in the upper airways can prevent spread of respiratory virus infection to the vulnerable lower airways. Activation of Toll-like receptor-2 (TLR2), when restricted to the nasal turbinates results in prompt induction of innate immune-driven anti-viral responses through action of cytokines, chemokines and cellular activity in the upper but not the lower airways. We define how nasal epithelial cells and recruitment of macrophages work in concert and play pivotal roles to limit progression of influenza virus to the lungs and sustain protection for up to seven days. These results reveal underlying mechanisms of how control of viral infection in the upper airways can occur and also support the implementation of strategies that can activate TLR2 in nasal passages to provide rapid protection, especially for at-risk populations, against severe respiratory infection when vaccines and antiviral drugs are not always effective or available.

Supplemental material

View

Version history
  • Version 1 (February 9, 2021): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI Insight

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement
Follow JCI Insight:
Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts